Home › Trial NCT03208556
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
- Trial IDNCT03208556
- StatusUnknown
- PhasePhase 1
- Study typeInterventional
- SponsorPeking University
- Enrollment20
- Start date2017-06-21
- ConditionsRelapsed or Refractory B-cell Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.